|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multicenter phase Ⅱ study of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck显示文摘 | Soulieres D Senzer NN Vokes EE | 2004 | J Clin Oncol2004，22，1： | 1 |
| 2 | Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picoma- virus, in advanced solid tumors with neuroendocrine features 显示文摘 | Rudin CM Poirier JT Senzer NN | 2011 | Clin Cancer Res2011，17，： | 1 |
| 3 | Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer显示文摘 | Sequist LV Gettinger S Senzer NN | 2010 | J Clin Oncol2010，28，33： | 1 |
| 4 | Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck 显示文摘 | Soulieres D Siu L | 2001 | Proc Am Soc Clin Oncol2001，20，： | 1 |
| 5 | Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck显示文摘 | Soulieres D Senzer NN Vokes EE | 2004 | J Clin Oncol2004，22，1： | 1 |
| 6 | Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma 显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 7 | Multicenter phase Ⅱ study of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck显示文摘 | Soulieres D Senzer NN Vokes EE | 2004 | J Clin Oncol2004，22，1： | 1 |
| 8 | Activity of IPl- 504,a novel heat-shock protein 90 inhibitor,in patients with molecularly defined non-small-cell lung cancer 显示文摘 | Sequist IN Gettinger S Senzer NN | 2010 | J Clin Oncol2010，28，33： | 1 |
| 9 | Multicenter phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck显示文摘 | Souli e res D Senzer NN Vokes EE | 2004 | Clin Oncol2004，22，： | 1 |
| 10 | Phase Ⅱ clinical trial of a granulocyte-macrophage colony-stimulating factorencoding,second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 11 | PhaseⅠ trial of irinotecan,infusional 5-fluorouracil,and leucovorin(FOLFIRI)with erlotinib:early termination due to increased toxicity显示文摘 | Messersmith WA Laheru DA Senzer NN | 2004 | Clin Cancer Res2004，10，19： | 1 |
| 12 | Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck 显示文摘 | Soulieres D Senzer NN Vokes EE | 2004 | J Clin Oncol2004，22，： | 1 |
| 13 | Activity of IPI-504,anovel heat-shock protein 90 inhibitor,in patients with molecularlydefined non-small-cell lung cancer 显示文摘 | Sequist LV GettingerS Senzer NN | 2010 | J Clin Oncol2010，28，49： | 1 |
| 14 | Phase 2 evaluation of OSI-774,a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck显示文摘 | Soulieres D Siu L | 2001 | Proc Am Soc Clin Oncol2001，20，： | 1 |
| 15 | Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck 显示文摘 | Soulieres D Senzer NN Vokes EE | 2004 | J Clin Oncol2004，22，： | 1 |
| 16 | Phase 11 clinical trial of a granuloeyte-maerophage colony-stimulat- ing factor-encoding, second-generation oneolytic her- pesvirus in patients with unresectable metastatic melanoma显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 17 | Multicenter phase Ⅱ study of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck显示文摘 | Soulieres D Senzer NN Vokes EE | 2004 | J Clin Oncol2004，22，1： | 1 |
| 18 | Phase II clinical trial of a ranulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma 显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 19 | Multicenter phase Ⅱ study of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck显示文摘 | Soulieres D Senzer NN Vokes EE | 2004 | J Clin Oncol2004，22，1： | 1 |
| 20 | Phase Ⅱ clinical trial of a granulocyte-macrophage colony-stimulating factor-enco- ding, second-generation oneolytic herpesvirus in patients with unre- sectable metastatic melanoma 显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员